ArticleJAMA network open2024
Long-Term Survival in Patients With Advanced Melanoma.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Article
- Long-Term Survival Heterogeneity Across PD-L1-Defined Subgroups in Pembrolizumab-Treated Non-Small-Cell Lung Cancer: A Model-Based Analysis.Pharmaceutics · 2026Article
- Geographic variation in the impact of novel melanoma therapies on mortality.Journal of the American Academy of Dermatology · 2026Article
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- Article
- Article
- Meta-analytic microbiome target discovery for immune checkpoint inhibitor response in advanced melanoma.Communications medicine · 2026Article
- RING finger E3 ubiquitin ligases: novel therapeutic opportunities in melanoma.Cellular & molecular biology letters · 2026Review
- Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.Nature reviews. Clinical oncology · 2026Review
- Sarcomatoid Squamous Cell Carcinoma and Its Mimics: A Meta-Analysis of Institutional Cases and Published Reports.Cancers · 2026Article
- Melanoma resists chemotherapy through an adaptive mitochondrial response.Journal of experimental & clinical cancer research : CR · 2026Article
- Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations.International journal of molecular sciences · 2026Review
- Precision medicine in cutaneous melanoma-A comprehensive review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- End‑of‑life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer center.BMC cancer · 2026Article
- Allostatic Load Predicts Immune-Related Toxicity and Survival in Melanoma Patients Receiving Immune Checkpoint Inhibitors.Cancers · 2026Article
- Cutaneous melanoma in Kazakhstan: epidemiological trends and economic burden on the healthcare system.Archives of public health = Archives belges de sante publique · 2026Article
- Sustained metabolic response in metastatic melanoma after intraperitoneal ozone therapy: a case report.AME case reports · 2026Article
- Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing.bioRxiv : the preprint server for biology · 2025Article
- Mechanisms of tumor persistence in metastatic melanoma following successful immunotherapy.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceLong-term survival data from clinical trials show that survival curves of patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) gradually reach a plateau, suggesting that patients have a chance of achieving long-term survival.
objectiveTo investigate long-term survival in patients with advanced melanoma treated with ICIs outside clinical trials. DESIGN, SETTING, AND
participantsCohort study using prospectively collected data from the nationwide Dutch Melanoma Treatment Registry, including patients in the Netherlands with advanced melanoma treated with first-line ICIs from 2012 to 2019. Data were analyzed from January to September 2023. EXPOSURES: Patients were treated with first-line ipilimumab-nivolumab, antibodies that target programmed cell death (anti-PD-1), or ipilimumab. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS) and melanoma-specific survival were analyzed, and a Cox proportional hazards model was used to investigate factors associated with PFS after reaching partial response (PR) or complete response (CR).
resultsA total of 2490 patients treated with first-line ICIs were included (median [IQR] age, 65.0 [55.3-73.0] years; 1561 male patients [62.7%]). Most patients had an Eastern Cooperative Oncology Group Performance Status of 1 or lower (2202 patients [88.5%]) and normal lactate dehydrogenase levels (1715 patients [68.9%]). PFS for all patients was 23.4% (95% CI, 21.7%-25.2%) after 3 years and 19.7% (95% CI, 18.0%-21.4%) after 5 years. Overall survival for all patients was 44.0% (95% CI, 42.1%-46.1%) after 3 years and 35.9% (95% CI, 33.9%-38.0%) after 5 years. Patients with metastases in 3 or more organ sites had a significantly higher hazard of progression after reaching PR or CR (adjusted hazard ratio, 1.37; 95% CI, 1.11-1.69). CONCLUSIONS AND RELEVANCE: This cohort study of patients with advanced melanoma treated with ICIs in clinical practice showed that their survival reached a plateau, comparable with patients participating in clinical trials. These findings can be used in daily clinical practice to guide long-term surveillance strategies and inform both physicians and patients regarding long-term treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.